BACKGROUND AND OBJECTIVE: Despite their widespread use in metastatic bone disease, some bisphosphonate drugs are associated with adverse events (AEs), particularly renal toxicity, adding to treatment burdens and increasing healthcare costs. Ibandronic acid is a single-nitrogen bisphosphonate with high efficacy against bone events and metastatic bone pain, and a renal safety profile compar- able to that of placebo. In this study, the safety of ibandronic acid was examined over a period of 4 years. PATIENTS AND METHODS: During an initial 96-week period, breast cancer patients with bone metastases were randomised in double-blind fashion to placebo or ibandronic acid 6mg administered by intravenous infusion over 1-2 hours every 3-4 weeks as part of a previously reported phase III trial (MF 4265 study). All patients completing the phase III trial were offered open-label active treatment for a further 96 weeks (extension phase). A total of 62 patients receivedibandronic acid 6mg in this extension phase and were classified according to their initial treatment (placebo/ibandronic acid 6mg [placebo/6mg] and ibandronic acid 6mg/ibandronic acid 6mg [6mg/6mg] groups). Safety was assessed by AE reports and clinical laboratory evaluations. RESULTS: During the 4-year study, most patients experienced at least one AE, with malignancy progression being most commonly reported. However, fewer treatment-related AEs were reported in the extension phase (placebo/6mg: 6.3% [1/16]; 6mg/6mg: 13.0% [6/46]) than in the initial phase of the study (placebo: 56.3% [9/16]; 6mg: 67.4% [31/46]). Serious AEs were mainly due to malignancy progression. There were no clinically relevant renal AEs, and in both groups, serum creatinine levels were similar for up to 4 years. CONCLUSION: This 96-week open-label safety extension of a phase III, placebo-controlled trial demonstrates that long-term use of intravenous ibandronic acid is well tolerated.
RCT Entities:
BACKGROUND AND OBJECTIVE: Despite their widespread use in metastatic bone disease, some bisphosphonate drugs are associated with adverse events (AEs), particularly renal toxicity, adding to treatment burdens and increasing healthcare costs. Ibandronic acid is a single-nitrogen bisphosphonate with high efficacy against bone events and metastatic bone pain, and a renal safety profile compar- able to that of placebo. In this study, the safety of ibandronic acid was examined over a period of 4 years. PATIENTS AND METHODS: During an initial 96-week period, breast cancerpatients with bone metastases were randomised in double-blind fashion to placebo or ibandronic acid 6mg administered by intravenous infusion over 1-2 hours every 3-4 weeks as part of a previously reported phase III trial (MF 4265 study). All patients completing the phase III trial were offered open-label active treatment for a further 96 weeks (extension phase). A total of 62 patients received ibandronic acid 6mg in this extension phase and were classified according to their initial treatment (placebo/ibandronic acid 6mg [placebo/6mg] and ibandronic acid 6mg/ibandronic acid 6mg [6mg/6mg] groups). Safety was assessed by AE reports and clinical laboratory evaluations. RESULTS: During the 4-year study, most patients experienced at least one AE, with malignancy progression being most commonly reported. However, fewer treatment-related AEs were reported in the extension phase (placebo/6mg: 6.3% [1/16]; 6mg/6mg: 13.0% [6/46]) than in the initial phase of the study (placebo: 56.3% [9/16]; 6mg: 67.4% [31/46]). Serious AEs were mainly due to malignancy progression. There were no clinically relevant renal AEs, and in both groups, serum creatinine levels were similar for up to 4 years. CONCLUSION: This 96-week open-label safety extension of a phase III, placebo-controlled trial demonstrates that long-term use of intravenous ibandronic acid is well tolerated.
Authors: L S Rosen; D Gordon; M Kaminski; A Howell; A Belch; J Mackey; J Apffelstaedt; M Hussein; R E Coleman; D J Reitsma; J J Seaman; B L Chen; Y Ambros Journal: Cancer J Date: 2001 Sep-Oct Impact factor: 3.360
Authors: S M Ali; F J Esteva; G Hortobagyi; H Harvey; J Seaman; R Knight; L Costa; A Lipton Journal: J Clin Oncol Date: 2001-07-15 Impact factor: 44.544
Authors: Lee S Rosen; David Gordon; Simon Tchekmedyian; Ronald Yanagihara; Vera Hirsh; M Krzakowski; M Pawlicki; Paul de Souza; Ming Zheng; Gladys Urbanowitz; Dirk Reitsma; John J Seaman Journal: J Clin Oncol Date: 2003-08-15 Impact factor: 44.544
Authors: Debasish Banerjee; Arif Asif; Liliane Striker; Richard A Preston; Jacques J Bourgoignie; David Roth Journal: Am J Kidney Dis Date: 2003-05 Impact factor: 8.860
Authors: Fred Saad; Donald M Gleason; Robin Murray; Simon Tchekmedyian; Peter Venner; Louis Lacombe; Joseph L Chin; Jeferson J Vinholes; J Allen Goas; Bee Chen Journal: J Natl Cancer Inst Date: 2002-10-02 Impact factor: 13.506
Authors: Lee S Rosen; David Gordon; Mary Kaminski; Anthony Howell; Andrew Belch; John Mackey; Justus Apffelstaedt; Mohamad A Hussein; Robert E Coleman; Dirk J Reitsma; Bee-Lian Chen; John J Seaman Journal: Cancer Date: 2003-10-15 Impact factor: 6.860
Authors: J-J Body; I J Diel; M R Lichinitser; E D Kreuser; W Dornoff; V A Gorbunova; M Budde; B Bergström Journal: Ann Oncol Date: 2003-09 Impact factor: 32.976
Authors: J J Body; I J Diel; M Lichinitzer; A Lazarev; M Pecherstorfer; R Bell; D Tripathy; B Bergstrom Journal: Br J Cancer Date: 2004-03-22 Impact factor: 7.640
Authors: Ingo J Diel; Andreas H A Kurth; Hans-Bernd Sittig; Harald Meden; Michael Maasberg; Andreas Sandermann; Raoul Bergner Journal: Support Care Cancer Date: 2010-02-12 Impact factor: 3.603
Authors: Mashari AlZahrani; Mark Clemons; Lisa Vandermeer; Marta Sienkiewicz; Arif Ali Awan; Brian Hutton; Gregory R Pond; Terry L Ng Journal: J Bone Oncol Date: 2020-11-10 Impact factor: 4.072